What Are the Real Benefits of CJC-1295? An Evidence Review

CJC-1295 at a glance:

• Drug class: Long-acting GHRH analog (research peptide)
• Route: subcutaneous injection (research use)
• Typical frequency: varies; once weekly (DAC) or daily (no-DAC) in user protocols
• Half-life: approximately 6-8 days (DAC version); ~30 minutes (no-DAC version)

The benefits of CJC-1295 are real but bounded. We separate evidence-supported benefits from popular but unsupported claims below.

Primary Benefit

Increased mean GH and IGF-1 levels in early-phase human studies.

That headline outcome is what most labels and trials are designed around. For CJC-1295: Teichman et al. 2006, JCEM — early human pharmacokinetic and pharmacodynamic data on CJC-1295 DAC.

Approved Indications

CJC-1295 is FDA-not approved for: none in the US.

Within those indications, the benefit is documented and reproducible. Outside them, evidence is weaker and the case for use depends on individual judgment.

Secondary and Pleiotropic Effects

Many drugs in this class have effects beyond their headline indication:

• Modest changes in body composition (lean mass, fat mass)
• Possible effects on sleep quality reported anecdotally
• IGF-1 elevation with downstream implications

Off-Label Considerations

Off-label use of CJC-1295 is variable. The case for off-label use is strongest when the underlying mechanism plausibly applies and weakest when it relies on extrapolation from related compounds.

Off-label use is legal but typically not insurance-covered, and the prescriber takes on responsibility for the decision.

What CJC-1295 Doesn't Do

A useful counterpoint to "benefits" is what's not supported by evidence:

• Provide a permanent fix that persists after stopping
• Replace lifestyle interventions (it makes them easier; it doesn't substitute for them)
• Produce effects that exceed what the underlying mechanism supports

Cost-Benefit Reasoning

Benefits are easier to evaluate when paired with cost. CJC-1295 costs varies, and the benefit needs to be weighed against that price tag and the side-effect burden documented elsewhere.

For most users, the benefit/cost calculation is positive when the medication is covered or accessible at a reasonable cash price; it shifts when neither is true.

Bottom Line

Benefits don't replace cost-benefit analysis. The right question isn't "does CJC-1295 have benefits?" but "do its benefits justify its costs and risks for me?"

Frequently Asked Questions

Related Reading

• CJC-1295 101: A Plain-English Guide for 2026
• CJC-1295 Side Effects: The Complete List and How to Handle Them
• Does CJC-1295 Really Work? An Evidence-Based Results Review
• The Real CJC-1295 Price Tag in 2026 — With and Without Insurance
• The Honest Guide to MK-677: What Patients and Doctors Actually Say
• Is MK-677 Safe? An Honest Look at the Side-Effect Profile

Sources

• Nass R et al. Effects of an Oral Ghrelin Mimetic on Body Composition in Healthy Older Adults. Annals of Internal Medicine 2008;149:601.
• Teichman SL et al. Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295. JCEM 2006;91:799.
• Stanley TL et al. Effects of Tesamorelin on Visceral Fat in HIV-Infected Patients With Lipodystrophy. NEJM 2010;363:2425.

This page summarizes published evidence and is not medical advice.